Factors Affecting Gastric Perforation Patient Outcome with History of Arthritis and Long Term Use of NSAIDs in Dr. Kariadi Semarang Period 2020 – 2022

Authors

  • Leonardo Cahyo Nugroho General Surgery, Faculty of Medicine, Duta Wacana Christian University Yogyakarta, Indonesia, Indonesia
  • Ardi Fauzi General Surgery, Faculty of Medicine, Diponegoro University Semarang, Indonesia, Indonesia
  • Agus Priambodo Orthopedic Surgery, Faculty of Medicine Diponegoro University Semarang, Indonesia, Indonesia

DOI:

https://doi.org/10.36408/mhjcm.v10i3.978

Keywords:

NSAIDs, Gastric Perforation, Arthritis, Scoring System

Abstract

Background: The incidence of gastric perforation gives a high mortality outcome. The second most common cause of gastric perforation is long-term use of NSAIDs. In cases of arthritis during the COVID-19 pandemic, a conservative therapeutic approach and administration of NSAIDs are preferred. Due to this, researchers want to know the factors affecting gastric perforation cause by NSAIDs.

Method: An analytic descriptive study with a retrospective cohort study design, using electronic medical records of patients at RSUP Dr. Kariadi Semarang from January 2020 - December 2022. Data collected was in the form of demographics, diagnoses, procedures, preoperative conditions, scoring system, and outcome.

Results: PULP score, one of prognostic factor, has a good level of significance compared to other scoring systems in determining the prognostic mortality of patients with gastric perforation. The combination of variables between the type of NSAIDs and the type of arthritis has a direct correlation with a positive inter-variable power of 86.7% and a significance of 0.049 on patient outcome.

Conclusion: NSAIDs pose a risk of gastric perforation in long-term use. tNSAIDs carry a higher risk inducing gastric perforation than selective NSAIDs.

Downloads

Download data is not yet available.

References

1. Dadfar A et al. Epidemiology of perforating peptic ulcer; World Journal of Gastroenterology; 2020

2. Andrew H soll. NSAID- Related Gastrointestinal Complication. Clinical Cornerstone- Upper GI disorder Vol 1 No. 5

3. Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78:16–24.

4. Bruye`re O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337–50

5. Enrico R, Mangiavini L, Vigano M, Brini Teresa A. Management of Osteoarthritis During COVID -19 Pandemic. Clinical Pharmacology & Therapeutics Volume 108 number 4, Milan, Oct 2020

6. Uimonen M, Kuitunen I, Paloneva J, Launonen AP, Ponkilainen V, Mattila VM (2021) The impact of the COVID-19 pandemic on waiting times for elective surgery patients: A multicenter study. PLoS ONE 16(7): e0253875

7. M. Hardian Basuki, Dampak COVID -19 terhadap layanan orthopaedi ; Ortho-Magz-Mei 2020

8. Ross, H. M, Pawlina, W. (2011). Histology (6th ed.). Philadelphia, PA: Lippincott Williams & Wilkins.

9. Mescher, A. L. (2013). Junquiera’s Basic Histology (13th ed.). New York, NY: McGraw-Hill Education

10. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol. 1990;12:260-266.

11. Kurata JH. An assessment of nonsteroid anti- inflammatory drugs as a risk factor in ulcer disease. Ann Intern Med. 1991; 114: 390-398.

12. Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal antiinflammatory drug-associated gastric ulcers do not require Helicobacter pylon’ for their development. Am J Gastroenterol. 1992;87: 1398-1402.

13. Ekstrom P, Carling L, Wetterhus S, Wingren PE, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Stand J Gastroenterol. 1996;31:753-758.

14. Stöllberger C, Finsterer J. Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. Vol. 92, Zeitschrift fur Kardiologie. 2003. p. 721–9.

15. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Vol. 112, Circulation. 2005. p. 759–70.

16. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Vol. 115, Circulation. 2007. p. 1634–42.

17. Hawkey CJ. COX-1 and COX-2 inhibitors. Best Practice and Research: Clinical Gastroenterology. 2001;15(5):801–20.

18. Varga Z, Sabzwari S rafay ali, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. 2017 Apr 8;

19. Qureshi O, Dua A. COX Inhibitors. Encyclopedia of Immunotoxicology [Internet]. 2021 Oct 19 [cited 2022 Jan 25];218–218. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549795

20. Topper JN, Cait J, Falbt D, Gimbrone MA, Steinberg D. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress (atherosclerosis/vascular endothelium/hemodynamic forces/differential display). Vol. 93, Medical Sciences. 1996

21. Tegeder I. COX-1 and COX-2 in Pain. In: Gebhart Gerald F. and Schmidt RF, editor. Encyclopedia of Pain [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 791–4. Available from: https://doi.org/10.1007/978-3-642-28753-4_915

22. Bunimov N, Laneuville O. Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis. Vol. 8, Cardiovascular & Haematological Disorders-Drug Targets. 2008.

23. Bruye`re O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337–50

24. Rapporto Osservasalute. Osservatorio sulla Salute. 2019. https://www.osservatoriosullasalute.it/ osservasalute/rapporto-osservasalute-2019. Accessed 14 Sept 2020

25. Report_XII SIMG 2019.pdf. 2019. https:// report.healthsearch.it/Report_XII.pdf. Accessed 14 Sept 2020.

26. Ariani A, Manara M, Fioravanti A, et al. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo. 2019;71: 5–21.

27. Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78:16–24.

28. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: Lessons learned from the cox-2 saga. Vol. 61, Annual Review of Medicine. 2010. p. 17–33.

29. Lombardi N, Crescioli G, Bettiol A, et al. Italian emergency department visits and hospitalizations for outpatients’ adverse drug events: 12-year active pharmacovigilance surveillance (The MEREAFaPS Study). Front Pharmacol. 2020;11:412

30. Scarpignato C, Bjarnason I. Drug-induced small bowel injury: a challenging and often forgotten clinical condition. Curr Gastroenterol Rep. 2019;21: 55.

 

Additional Files

Published

2023-11-29

How to Cite

1.
Nugroho LC, Fauzi A, Priambodo A. Factors Affecting Gastric Perforation Patient Outcome with History of Arthritis and Long Term Use of NSAIDs in Dr. Kariadi Semarang Period 2020 – 2022. Medica Hospitalia J. Clin. Med. [Internet]. 2023 Nov. 29 [cited 2024 May 26];10(3):324-33. Available from: http://medicahospitalia.rskariadi.co.id/medicahospitalia/index.php/mh/article/view/978

Issue

Section

Original Article

Citation Check